· *Gilead's stock fell 4% on Monday after a coronavirus drug trial showed mixed results in moderately ill people. *
· *The company tested the drug in patients who received the treatment for both 5 days and 10 days. *
· *Patients who received it for 5 days were 65% more likely to show signs of recovery than those who...
Gilead slides 4% after COVID-19 drug shows limited benefit in moderately ill patients
Business Insider
0 shares
1 views
You might like
Related news coverage
People are paying as much as $10,000 for an unlicensed remdesivir variant for their cats, in a thriving black market linked to Facebook groups
Business Insider
· A variant of remdesivir, one of the most promising treatments for COVID-19, has for more than a year been sold as a treatment..
-
NA Proactive news snapshot: Milestone Scientific, BetterLife Pharma, Revive Therapeutics, Matinas BioPharma, Biocept UPDATE …
Proactive Investors
-
NA Proactive news snapshot: Biocept, Globex Mining Enterprises, Q BioMed, ImagineAR UPDATE …
Proactive Investors
-
Gilead slaps multi-thousand-dollar price tag on coronavirus treatment remdesivir
Proactive Investors
-
Gilead prices coronavirus drug at $2,340 for rich countries
SeattlePI.com
Advertisement
More coverage
Remdesivir shows "limited benefit" during trial, so why did the FDA approve it?
NaturalNews.com
(Natural News) Remdesivir, the wonder drug touted to treat the Wuhan coronavirus (COVID-19), showed a “limited benefit” in a..